Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective

OBJECTIVE: To study cost-effectiveness of an interleukin (IL)-17A inhibitor secukinumab, with other biologics and apremilast in patients with Psoriatic arthritis (PsA) from payer perspective in Finland. METHODS: In this semi-Markov model, subcutaneous (SC) secukinumab was compared with SC treatments...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cost Eff Resour Alloc
Autors principals: Purmonen, Timo, Puolakka, Kari, Bhattacharyya, Devarshi, Jain, Minal, Martikainen, Janne
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2018
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6240184/
https://ncbi.nlm.nih.gov/pubmed/30479574
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12962-018-0162-3
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars